Impact of Lipoprotein (a) on Residual Cardiovascular Risk after an Acute Coronary Syndrome
Authors:
- Nelsa González -AguadoN-Nelsa González -Aguado
- Rafael Franco-HitaRFRafael Franco-Hita
- Jose Ignacio Larrubia-ValleJLJose Ignacio Larrubia-Valle
- Fernando Puyol-RuizFPFernando Puyol-Ruiz
- Ainhoa Robles-MezcuaARAinhoa Robles-Mezcua
- Jose Manuel García-PinillaJGJose Manuel García-Pinilla
- María Jiménez-SalvaMJMaría Jiménez-Salva
- Alberto Piserra-LópezAPAlberto Piserra-López
- Francisco Javier Pavon-MoronFrancisco Javier Pavon-Moron
- Alejandro Pérez-CabezaAPAlejandro Pérez-Cabeza
- Pierre SabouretPierre Sabouret
- Francesco CostaFCFrancesco Costa
Preprint
- 5 February 2026
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Reducing residual cardiovascular risk following an acute coronary syndrome (ACS) remains a major unmet clinical need. Despite substantial advances in lipid-lowering therapies, the risk of recurrent major adverse cardiovascular events (MACE) after ACS remains high, with an estimated incidence of approximately 33.4% at 5 years. Residual cardiovascular risk is driven by multiple mechanisms, including persistent inflammation, a prothrombotic status, metabolic disturbances, and the presence of atherogenic lipoproteins beyond low-density lipoprotein cholesterol (LDL-C). Lipoprotein(a) [Lp(a)] is a pro-inflammatory, pro-thrombotic and pro-atherosclerotic lipoprotein which seems to play a major role in the residual risk post ACS or atherosclerotic ischemic stroke. Elevated Lp(a) is a well-established independent and causal risk factor for atherosclerotic cardiovascular disease (ASCVD). Nevertheless, evidence regarding its prognostic value specifically after ACS remains limited, with marked heterogeneity across studies, which complicates direct comparisons and interpretation. In addition, while Lp(a) levels are predominantly genetically determined, recent studies have reported intra-individual variability, although its clinical significance remains uncertain. Finally, current therapeutic options specifically targeting Lp(a) are limited. Novel RNA-based therapies, including antisense oligonucleotides, small interfering RNAs, and emerging gene-editing approaches, have demonstrated profound and sustained reductions in circulating Lp(a) levels. Yet, whether this biological effect translates into reductions of hard clinical endpoints is under evaluation in ongoing clinical trials. This review aims to synthesize current evidence on the role Lp(a) as a major contributor to residual cardiovascular risk following ACS.Keywords
All Related Versions
This publication has 100 references indexed in Scilit:
- Design and Rationale of Lp(a)HORIZON Trial: Assessing the Effect of Lipoprotein(a) Lowering With Pelacarsen on Major Cardiovascular Events in Patients With CVD and Elevated Lp(a)American Heart Journal, 2025
- Oral Muvalaplin for Lowering of Lipoprotein(a)JAMA, 2025
- Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein(a)JAMA, 2024
- Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a)JAMA, 2023
- Circulating lipoprotein (a) and all-cause and cause-specific mortality: a systematic review and dose-response meta-analysisEuropean Journal of Epidemiology, 2023
- Lipoprotein(a) levels and risk of adverse events after myocardial infarction in patients with and without diabetesJournal of Thrombosis and Thrombolysis, 2022
- Lipoprotein(a) and its Significance in Cardiovascular DiseaseJAMA Cardiology, 2022
- A Review of the Clinical Pharmacology of Pelacarsen: A Lipoprotein(a)-Lowering AgentAmerican Journal of Cardiovascular Drugs, 2021
- Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary SyndromeJAMA Cardiology, 2018
- Effect of Alirocumab on Lipoprotein(a) Over ≥1.5 Years (from the Phase 3 ODYSSEY Program)The American Journal of Cardiology, 2017